|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007102,
umls-concept:C0072980,
umls-concept:C0123931,
umls-concept:C0127400,
umls-concept:C0205195,
umls-concept:C0334227,
umls-concept:C0441655,
umls-concept:C0679729,
umls-concept:C1414805,
umls-concept:C1515655,
umls-concept:C1522496,
umls-concept:C1533691,
umls-concept:C1706089,
umls-concept:C1709059
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-2-20
|
|
pubmed:abstractText |
Despite recent progress, colon cancer is often resistant to combination chemotherapy, highlighting the need for development of novel therapeutic approaches. An attractive target is hypoxia-inducible factor-1alpha (HIF-1alpha), a key transcription factor with a pivotal role in tumor cell metabolism. One potential class of therapeutic agents targeting HIF-1alpha are mammalian target of rapamycin inhibitors such as rapamycin. A second class are topoisomerase I inhibitors, such as irinotecan, which are able to inhibit the accumulation of HIF-1alpha. We here investigated whether combination of rapamycin and irinotecan was active in human colon cancer models.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/HIF1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoxia-Inducible Factor 1, alpha...,
http://linkedlifedata.com/resource/pubmed/chemical/MTOR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylinositol 3-Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan,
http://linkedlifedata.com/resource/pubmed/chemical/mTOR protein, mouse
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1297-307
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19190131-Animals,
pubmed-meshheading:19190131-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19190131-Camptothecin,
pubmed-meshheading:19190131-Cell Line, Tumor,
pubmed-meshheading:19190131-Colonic Neoplasms,
pubmed-meshheading:19190131-Glycolysis,
pubmed-meshheading:19190131-Humans,
pubmed-meshheading:19190131-Hypoxia-Inducible Factor 1, alpha Subunit,
pubmed-meshheading:19190131-MAP Kinase Signaling System,
pubmed-meshheading:19190131-Male,
pubmed-meshheading:19190131-Mice,
pubmed-meshheading:19190131-Phosphatidylinositol 3-Kinases,
pubmed-meshheading:19190131-Protein Kinases,
pubmed-meshheading:19190131-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:19190131-Sirolimus,
pubmed-meshheading:19190131-TOR Serine-Threonine Kinases,
pubmed-meshheading:19190131-Tumor Suppressor Protein p53,
pubmed-meshheading:19190131-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
|
|
pubmed:affiliation |
Institut National de la Santé et de la Recherche Médicale U682, Service de Biochimie et Biologie Moléculaire, Hôpital de Hautepierre Hôpitaux Universitaires de Strasbourg, Strasbourg, France. erwan.pencreach@chru-strasbourg.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
